Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone

Royalty Pharma plc

2022-FY EPS reported $0.10 revenue$2,237,215,000

Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).
Q4 GAAP operating cash flow $570M (+16% YoY); FY $2,144M (+6%).
Announced transactions up to $3.5B in 2022, including $2.0B in upfront payments.
FY 2023 guidance: Adj Cash Receipts $2,375M-$2,475M, underlying growth 4-9% prior to Biohaven payments; excludes potential $475M zavegepant milestone.
In 2023, agreed to provide $500M upfront to Ionis Pharmaceuticals for a new partnership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Royalty Pharma plc updated its the quarter and year ended December 31, 2022 guidance (initiated).

Period: the quarter and year ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

On February 15, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.